Literature DB >> 3306266

Clinical features and management of poisoning due to antimalarial drugs.

A Jaeger, P Sauder, J Kopferschmitt, F Flesch.   

Abstract

The toxicities of antimalarial drugs vary because of the differences in the chemical structures of these compounds. Quinine, the oldest antimalarial, has been used for 300 years. Of the 200 to 300 compounds synthesised since the first synthetic antimalarial, primaquine in 1926, 15 to 20 are currently used for malaria treatment, most of which are quinoline derivatives. Quinoline derivatives, particularly quinine and chloroquine, are highly toxic in overdose. The toxic effects are related to their quinidine-like actions on the heart and include circulatory arrest, cardiogenic shock, conduction disturbances and ventricular arrhythmias. Additional clinical features are obnubilation, coma, convulsions, respiratory depression. Blindness is a frequent complication in quinine overdose. Hypokalaemia is consistently present, although apparently self-correcting, in severe chloroquine poisoning and is a good index of severity. Recent toxicokinetic studies of quinine and chloroquine showed good correlations between dose ingested, serum concentrations and clinical features, and confirmed the inefficacy of haemodialysis, haemoperfusion and peritoneal dialysis for enhancing drug removal. The other quinoline derivatives appear to be less toxic. Amodiaquine may induce side effects such as gastrointestinal symptoms, agranulocytosis and hepatitis. The main feature of primaquine overdose is methaemoglobinaemia. No cases of mefloquine and piperaquine overdose have been reported. Overdose with quinacrine, an acridine derivative, may result in nausea, vomiting, confusion, convulsion and acute psychosis. The dehydrofolate reductase inhibitors used in malaria treatment are sulfadoxine, dapsone, proguanil (chloroguanide), trimethoprim and pyrimethamine. Most of these drugs are given in combination. Proguanil is one of the safest antimalarials. Convulsion, coma and blindness have been reported in pyrimethamine overdose. Sulfadoxine can induce Lyell and Stevens-Johnson syndromes. The main feature of dapsone poisoning is severe methaemoglobinaemia which is related to dapsone and to its metabolites. Recent toxicokinetic studies confirmed the efficacy of oral activated charcoal, haemodialysis and haemoperfusion in enhancing removal of dapsone and its metabolites. No overdose has been reported with artemesinine, a new antimalarial tested in the People's Republic of China. The general management of antimalarial overdose include gastric lavage and symptomatic treatment.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3306266     DOI: 10.1007/BF03259868

Source DB:  PubMed          Journal:  Med Toxicol Adverse Drug Exp        ISSN: 0113-5244


  123 in total

1.  Cardiovascular effects of chloroquine with special reference to its antifibrillatory action.

Authors:  M E HESS; C F SCHMIDT
Journal:  Circ Res       Date:  1959-01       Impact factor: 17.367

2.  Quinine amblyopia treated by hemodialysis.

Authors:  M Floyd; A V Hill; B J Ormston; R Menzies; R Porter
Journal:  Clin Nephrol       Date:  1974 Jan-Feb       Impact factor: 0.975

3.  Drug resistance of malaria parasites in Tanzania.

Authors:  D F Clyde
Journal:  East Afr Med J       Date:  1966-10

4.  The polymorphic acetylation of dapsone in man.

Authors:  R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

5.  Chloroquine intoxication.

Authors:  M Frisk-Holmberg; Y Bergqvist; U Englund
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

6.  Studies of the disposition and metabolism of mefloquine HCl (WR 142,490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR 30,090.

Authors:  J Y Mu; Z H Israili; P G Dayton
Journal:  Drug Metab Dispos       Date:  1975 May-Jun       Impact factor: 3.922

7.  Quinine-induced alterations in drug disposition.

Authors:  C M Berlin; J M Stackman; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

8.  [Tissue distribution of chloroquine in 18 cases of voluntary poisoning].

Authors:  J Mondain; G Gras; P D Ndiaye
Journal:  Bull Soc Pathol Exot Filiales       Date:  1979 Jan-Feb

9.  Acute dapsone intoxication: clinical findings and effect of oral charcoal and haemodialysis on dapsone elimination.

Authors:  P J Neuvonen; E Elonen; E J Haapanen
Journal:  Acta Med Scand       Date:  1983

10.  Plasma kinetics and urinary excretion of primaquine in man.

Authors:  J Greaves; D A Evans; H M Gilles; K A Fletcher; D Bunnag; T Harinasuta
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

View more
  24 in total

1.  Management of dapsone poisoning complicated by methaemoglobinaemia.

Authors:  A H Dawson; I M Whyte
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct

2.  Safety of computerized drug management: a case report.

Authors:  K-A Nguyen; T Vial; F Gueyffier; S Marignier; P Cochat; B Kassai
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

3.  Delayed therapeutic hypothermia following cardiac arrest secondary to chloroquine toxicity.

Authors:  George Mark Haslam; Matt C Thomas; Stephen R Laver
Journal:  BMJ Case Rep       Date:  2009-03-06

Review 4.  Antimalarial agents: specific chemoprophylaxis regimens.

Authors:  B L Herwaldt; D J Krogstad; P H Schlesinger
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

Review 5.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy.

Authors:  Sadhna M Shankar; Joseph J Nania
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 7.  CNS adverse events associated with antimalarial agents. Fact or fiction?

Authors:  P A Phillips-Howard; F O ter Kuile
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

8.  Inhibition of Kir4.1 potassium channels by quinacrine.

Authors:  Leticia G Marmolejo-Murillo; Iván A Aréchiga-Figueroa; Meng Cui; Eloy G Moreno-Galindo; Ricardo A Navarro-Polanco; José A Sánchez-Chapula; Tania Ferrer; Aldo A Rodríguez-Menchaca
Journal:  Brain Res       Date:  2017-03-11       Impact factor: 3.252

9.  Amrinone for refractory cardiogenic shock following chloroquine poisoning.

Authors:  P Hantson; J L Ronveau; B De Coninck; J L Horn; P Mahieu; A Hassoun
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 10.  Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes.

Authors:  Bernard J Brabin; Teunis A Eggelte; Monica Parise; Francine Verhoeff
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.